Peltekian KM

Idioma: Ingles.
Referencias bibliográficas: 9
Paginas: 4-5
Archivo PDF: 75.51 Kb.

FRAGMENTO

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Hinz M, Wree A, Jochum Ch, Bechmann LP, Saner F, Gerbes AL, Gerken G, et al. High age and low sodium urine concentration are associated with poor survival in patients with hepatorenal syndrome. Ann Hepatol 2013; 12: 92-9.

2. Testro AG, Wongseelashote S, Angus PW, Gow PJ. Longterm outcome of patients with treated with terlipressin for types 1 and 2 hepatorenal syndrome. J Gastroenterol Hepatol 2008; 23: 1535-40.

3. Muñoz LE, Alcalá EG, Cordero P, Martínez MA, Vázquez NY, Galindo S, Mendoza E, et al. Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin and albumin: first experience in Mexico. Ann Hepatol 2009; 8: 207-11.

4. Al Hamoudi W, Lee SS. Cirrhotic cardiomyopathy. Ann Hepatol 2006; 5: 132-9.

5. Odilson Marcos Silvestre, Fernando Bacal, Danusa de Souza Ramos, Jose L. Andrade, Meive Furtado, Vincenzo Pugliese, Elisangela Belleti, et al. Impact of the severity of end-stage liver disease in cardiac structure and function. Ann Hepatol 2013; 12: 85-91.

6. Coelho HSM, Villela-Nogueira CA. Predictors of response to chronic hepatitis C treatment. Ann Hepatol 2010; 9: S54-S60.

7. Lin C-Y, Sheen I-S, Jeng W-J, Huang C-W, Huang C-H, Chen J-Y. Patients younger than forty years old with hepatitis C virus genotype-1 chronic infection had treatment responses similar to genotype-2 infection and not related to interleukin-28B polymorphism. Ann Hepatol 2013; 12:62-9.

8. Abdelfattah M. Attallah, Sanaa O. Abdallah, Ahmed A. Attallah, Mohamed M. Omran, Khaled Farid, Wesam A. Nasif, Gamal E. Shiha, et al. Diagnostic value of fibronectin discriminant score for predicting liver fibrosis stages in chronic hepatitis C virus patients. Ann Hepatol 2013; 12: 44-53.

9. De Torres M, Poynard T. Risk factors for liver fibrosis progression in patients with chronic hepatitis C. Ann Hepatol 2003; 2: 5-11.